Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-225-PP13D3
- Development stage
- Preclinical
- Lead developer
- Molecular Targeting Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Ac-225-PP13D3 is an investigational targeted radiotherapeutic (TRT) developed by Molecular Targeting Technologies (MTTI). It is a targeted alpha therapy (TAT) consisting of the targeting ligand PP13D3 radiolabeled with the alpha-emitting isotope actinium-225 (Ac-225). The drug is designed to treat neuroendocrine tumors (NETs) and prostate cancer by delivering high-energy alpha radiation directly to tumor cells. Alpha particles are characterized by high linear energy transfer (LET) and a very short range (typically 50–100 μm), which allows for the induction of lethal double-strand DNA breaks in cancer cells while minimizing damage to surrounding healthy tissue. The PP13D3 ligand is part of MTTI's platform designed to optimize the pharmacokinetic profile and tumor uptake of the radiopharmaceutical. As of early 2024, the program is in the preclinical stage, with activities focused on filing an Investigational New Drug (IND) application.
- Other names
- Actinium-225 PP13D3Actinium225 PP13D3Actinium 225 PP13D3
02
Targets
DNAPSMA (Prostate-specific membrane antigen)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on Ac-225-PP13D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ac-225-PP13D3.